• 1
    Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004; 126: 40213.
  • 2
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350: 87685.
  • 3
    Colombel FJ, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132: 5265.
  • 4
    Sandborn WJ, Rutgeerts P, Ems R, et al. Adalimumab induction therapy for Crohn’s disease previously treated with infliximab. Ann Intern Med 2007; 146: 82938.
  • 5
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 246276.
  • 6
    Gisbert JP, Gonzalez-Lama Y, Maté J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007; 25: 1937.
  • 7
    Baert F, Norman M, Vermeire S, et al. Influence of immunogenicity on the long term efficacy of infliximab in Crohn’s disease. N Eng J Med 2003; 348: 6018.
  • 8
    Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007; 13: 232832.
  • 9
    Oussalah A, Laclotte C, Chevaux JB, et al. Long-term outcome of adalimumab for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008; 28: 96672.
  • 10
    Afif W, Leighton JA, Hanauer SB, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009; 15: 13027.
  • 11
    Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Ulcerative colitis clinical classification. Can J Gastroenterol 2005; 19(Suppl. A): 9A13A.
  • 12
    Colombel JF, Sandborn WJ, Reinisch W, et al. , SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362: 138395.
  • 13
    Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 18618.
  • 14
    Reinisch W, Lofberg R, Louis E, et al. Adalimumab effectiveness in TNF-antagonist-naive patients and in infliximab nonresponders with Crohn’s disease: results from the CARE study. Am J Gastroenterol 2008; 103: A1068.
  • 15
    Seiderer J, Brand S, Dambacher J, et al. Adalimumab in patients with Crohn’s disease – safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther 2007; 25: 78796.
  • 16
    Ho GT, Mowat A, Potts L, et al. Efficacy and complications of adalimumab treatment for medically-refractory Crohn’s disease: analysis of nationwide experience in Scotland (2004-2008). Aliment Pharmacol Ther 2009; 29: 52734.
  • 17
    Barreiro-de Acosta M, Lorenzo A, Dominguez-Muñoz JE. Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years. World J Gastroenterol 2009; 15: 38146.
  • 18
    Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis. Gastroenterology 2010; 138(Suppl. 1): S-1145.
  • 19
    Loftus EV, Delgado DJ, Friedman HS, Sandborn WJ. Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States. Am J Gastroenterol 2008; 103: 173745.
    Direct Link:
  • 20
    Lepisto A, Luukkonen P, Jarvinen HJ. Cumulative failure rate of ileal pouch-anal anastomosis and quality of life after failure. Dis Colon Rectum 2002; 45: 128994.
  • 21
    Tulchinsky H, Hawley PR, Nicholls J. Long-term failure after restorative proctocolectomy for ulcerative colitis. Ann Surg 2003; 238: 22934.
  • 22
    Johnson P, Richard C, Ravid A, et al. Female infertility after ileal pouchanal anastomosis for ulcerative colitis. Dis Colon Rectum 2004; 47: 111926.
  • 23
    Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 125060.
  • 24
    Ferrante M, Vermiere S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohn’s Colitis 2008; 2: 21925.
  • 25
    Gies N, Kroeker I, Wong K, et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther 2010; 32: 5228.
  • 26
    Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 11339.